Cancer Research SABCS  Protein Translation and Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Saito, R.
Right arrow Articles by Bankiewicz, K. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Saito, R.
Right arrow Articles by Bankiewicz, K. S.
[Cancer Research 64, 6858-6862, October 1, 2004]
© 2004 American Association for Cancer Research


Advances in Brief

Convection-Enhanced Delivery of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand with Systemic Administration of Temozolomide Prolongs Survival in an Intracranial Glioblastoma Xenograft Model

Ryuta Saito, John R. Bringas, Amith Panner, Matyas Tamas, Russell O. Pieper, Mitchel S. Berger and Krystof S. Bankiewicz

Brain Tumor Research Center, Department of Neurological Surgery, University of California at San Francisco, San Francisco, California

Although tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a potent activator of cell death, preferentially killing neoplastic cells over normal cells, the efficacy of TRAIL for the treatment of glioma might be limited due to cellular resistance and, importantly, poor distribution after systemic administration. TRAIL and temozolomide (TMZ) were recently shown to have a synergistic antitumor effect against U87MG glioma cells in vitro. Convection-enhanced delivery (CED) can effectively distribute TRAIL protein throughout a brain tumor mass. In this study, we evaluated CED of TRAIL, alone and in conjunction with systemic TMZ administration, for antitumor efficacy. CED of TRAIL demonstrated safe and effective distribution in both normal brain and a U87MG intracranial xenograft model. Individually, both CED of TRAIL and systemic TMZ administration prolonged survival in tumor-bearing rats. However, the combination of these two treatments was significantly more effective than either treatment alone. CED of TRAIL in conjunction with systemic TMZ treatment is a promising strategy for the treatment of malignant gliomas.




This article has been cited by other articles:


Home page
Neuro Oncol DukeHome page
M. Uzzaman, G. Keller, and I. M. Germano
In vivo gene delivery by embryonic-stem-cell-derived astrocytes for malignant gliomas
Neuro-oncol, January 1, 2009; 11(2): 102 - 108.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
S. Hingtgen, X. Ren, E. Terwilliger, M. Classon, R. Weissleder, and K. Shah
Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide
Mol. Cancer Ther., November 1, 2008; 7(11): 3575 - 3585.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
D. S. Ziegler, A. L. Kung, and M. W. Kieran
Anti-Apoptosis Mechanisms in Malignant Gliomas
J. Clin. Oncol., January 20, 2008; 26(3): 493 - 500.
[Abstract] [Full Text] [PDF]


Home page
Neuro Oncol DukeHome page
J. H. Sampson, G. Akabani, G. E. Archer, M. S. Berger, R. E. Coleman, A. H. Friedman, H. S. Friedman, K. Greer, J. E. Herndon II, S. Kunwar, et al.
Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors
Neuro-oncol, January 1, 2008; 10(3): 320 - 329.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
B. Yamini, X. Yu, P. Pytel, N. Galanopoulos, V. Rawlani, J. Veerapong, K. Bickenbach, and R. R. Weichselbaum
Adenovirally Delivered Tumor Necrosis Factor-{alpha} Improves the Antiglioma Efficacy of Concomitant Radiation and Temozolomide Therapy
Clin. Cancer Res., October 15, 2007; 13(20): 6217 - 6223.
[Abstract] [Full Text] [PDF]


Home page
Neuro Oncol DukeHome page
M. T. Krauze, C. O. Noble, T. Kawaguchi, D. Drummond, D. B. Kirpotin, Y. Yamashita, E. Kullberg, J. Forsayeth, J. W. Park, and K. S. Bankiewicz
Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts
Neuro-oncol, October 1, 2007; 9(4): 393 - 403.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. E. Wohlfahrt, B. C. Beard, A. Lieber, and H.-P. Kiem
A Capsid-Modified, Conditionally Replicating Oncolytic Adenovirus Vector Expressing TRAIL Leads to Enhanced Cancer Cell Killing in Human Glioblastoma Models
Cancer Res., September 15, 2007; 67(18): 8783 - 8790.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. Rousseau, C. Boudou, R. F. Barth, J. Balosso, F. Esteve, and H. Elleaume
Enhanced Survival and Cure of F98 Glioma Bearing Rats following Intracerebral Delivery of Carboplatin in Combination with Photon Irradiation
Clin. Cancer Res., September 1, 2007; 13(17): 5195 - 5201.
[Abstract] [Full Text] [PDF]


Home page
Neuro Oncol DukeHome page
j. H. Sampson, R. Raghavan, M. L. Brady, j. M. Provenzale, j. E. Herndon II, D. Croteau, A. H. Friedman, D. A. Reardon, R. E. Coleman, T. Wong, et al.
Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions
Neuro-oncol, July 1, 2007; 9(3): 343 - 353.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Roentgenol.Home page
J. H. Sampson, R. Raghavan, J. M. Provenzale, D. Croteau, D. A. Reardon, R. E. Coleman, I. R. Ponce, I. Pastan, R. K. Puri, and C. Pedain
Induction of Hyperintense Signal on T2-Weighted MR Images Correlates with Infusion Distribution from Intracerebral Convection-Enhanced Delivery of a Tumor-Targeted Cytotoxin
Am. J. Roentgenol., March 1, 2007; 188(3): 703 - 709.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
M. I. Dorrell, E. Aguilar, L. Scheppke, F. H. Barnett, and M. Friedlander
Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis
PNAS, January 16, 2007; 104(3): 967 - 972.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
T. Kawaguchi, Y. Yamashita, M. Kanamori, R. Endersby, K. S. Bankiewicz, S. J. Baker, G. Bergers, and R. O. Pieper
The PTEN/Akt Pathway Dictates the Direct {alpha}V{beta}3-Dependent Growth-Inhibitory Action of an Active Fragment of Tumstatin in Glioma Cells In vitro and In vivo
Cancer Res., December 1, 2006; 66(23): 11331 - 11340.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
Y.-C. Li, C.-C. Tzeng, J. H. Song, F.-J. Tsia, L.-J. Hsieh, S.-J. Liao, C.-H. Tsai, E. G. Van Meir, C. Hao, and C.-C. Lin
Genomic alterations in human malignant glioma cells associate with the cell resistance to the combination treatment with tumor necrosis factor-related apoptosis-inducing ligand and chemotherapy.
Clin. Cancer Res., May 1, 2006; 12(9): 2716 - 2729.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Eramo, R. Pallini, F. Lotti, G. Sette, M. Patti, M. Bartucci, L. Ricci-Vitiani, M. Signore, G. Stassi, L. M. Larocca, et al.
Inhibition of DNA Methylation Sensitizes Glioblastoma for Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Mediated Destruction
Cancer Res., December 15, 2005; 65(24): 11469 - 11477.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.